The global Crohn’s disease (CD) treatment market is projected to reach a value of approximately US$ 17.80 billion by the end of 2033, up from US$ 11.68 billion at the end of 2023. This growth, which represents a steady compound annual growth rate (CAGR) of 4.3% over the next decade, is primarily fueled by the increasing incidence of Crohn’s disease and ulcerative colitis worldwide, according to a recent report by Future Market Insights.
The rise in Crohn’s disease and ulcerative colitis cases globally acts as a significant driver for the growth of the treatment market. The growing awareness and prevalence of these conditions contribute to the robust market expansion. Enhanced treatment options including the use of biologics such as adalimumab, infliximab, certolizumab, and golimumab have further propelled the market forward.
Request for a Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16809
Statistical insights from an NCBI article in 2020 highlight that ulcerative colitis affects 9 to 20 per 100,000 individuals annually, with the highest incidence rates observed in North America and Europe—156 to 291 cases per year. This increase in ulcerative colitis incidence directly correlates with the rising demand for effective Crohn’s disease treatments, further stimulating market growth.
In addition, significant advancements in therapeutic strategies and collaborations among key players in the industry are expected to drive market growth. A notable example of such collaboration is the April 2022 partnership between the Crohn’s & Colitis Foundation and Inotrem, a biotech company specializing in the development of immune checkpoint inhibitors for inflammatory syndromes. This partnership aims to support the development of innovative therapeutic approaches specifically for Crohn’s disease, signaling potential growth opportunities in the market.
“The ongoing collaborations and innovations in the treatment of inflammatory bowel diseases, particularly Crohn’s disease, are crucial for meeting the increasing demand for effective therapies,” said at Future Market Insights. “These developments not only aim to improve patient outcomes but also broaden the horizon of therapeutic possibilities in the global Crohn’s disease treatment market.”
As the market continues to evolve, stakeholders are optimistic about the introduction of more advanced and effective treatment modalities, which are expected to significantly enhance patient quality of life and management of Crohn’s disease symptoms.
Key Takeaways from the Market Study:
- The Crohn’s disease treatment market expanded historically between 2018 and 2022 at a CAGR of 3.2%.
- More than $11.2 billion is presently spent on treating Crohn’s disease globally.
- Immunomodulators are predicted to lead the medication type sector in 2023 with a 53% revenue share.
- The hospital pharmacy sector by distribution channel will maintain the second-largest segment during the anticipated period, with a global market share of 27.3% in 2023.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 4.9%.
- From 2023 to 2033, the Asia Pacific Crohn’s Disease Treatment Market is anticipated to expand at a stable CAGR of 3.6%.
“The increasing prevalence of ulcerative colitis and Crohn’s disease along with innovative pipeline of biological therapies and medications are expected to accelerate the growth during the forecast period,” comments a Future Market Insights analyst.
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16809
Competitive Landscape:
Some of the top players in the global intraocular lymphoma disease market are:
- Abbvie Inc.
- Celgene Corporation
- Genetech
- Johnson & Johnson
- Pfizer
- Prometheus Laboratories Inc. (Nestle)
- Salix Pharmaceuticals Inc.
- Takeda’s Pharmaceutical Ltd
- Janssen Pharmaceuticals
- Biogen
- AstraZeneca
Some of the recent developments in this domain are:
- In 2022, AbbVie said that SKYRIZI® (risankizumab-rzaa) has received FDA approval to be used in the management of moderately to highly active Crohn’s disease. The interleukin-23 (IL-23) inhibitor SKYRIZI binds to the p19 component of IL-23 to specifically inhibit it. A variety of chronic immune-mediated disorders, including Crohn’s disease, are suspected to be related to IL-23, a cytokine implicated in inflammatory processes.
- Tiziana Life Sciences, a biotechnology firm that enables breakthrough immunotherapies through innovative modes of monoclonal antibody administration, announced the start of a Phase 1b clinical study in 2022 to test foralumab enteric-coated capsules orally delivered in people who have mild to moderate Crohn’s Disease (CD). A unique method of inducing an anti-inflammatory immune reaction by site-targeted immunomodulation in the intestine is oral administration of foralumab.
Key Segments Covered in the Crohn’s Disease Treatment Market Report:
By Drug Type:
- Antibiotics
- Amino Salicylates
- Corticosteroids
- Immunomodulators
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/16809
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
